What compounding changes

Compounding means a pharmacist, doctor, or registered outsourcing facility makes a drug in place of a finished FDA-approved product.

The Food and Drug Administration is known as FDA. In the position checked September 2026, compounding has a role if no approved drug meets the person’s medical need, or if the approved drug is unavailable.

In the September 2026 framework, an outsourcing facility registers with FDA for making sterile drugs. Sterile describes the absence of living germs.

Compounded drugs had no FDA approval in the position checked September 26, 2026. FDA has not checked them for safety, for how well they work, or for quality before marketing.

A state license leaves that limit in place.

The 503A route generally starts with a valid prescription naming the person who needs the medicine. Under the rules checked September 2026, it must be made by a doctor with a license, or by a pharmacist with a license working in a state-licensed pharmacy or federal facility. The maker and the drug must also meet the law’s other conditions. The next section covers the raw ingredient test. Ask the pharmacist which conditions apply to the proposed preparation and how each is met.

The 503B route is for an outsourcing facility that registers with FDA to make sterile drugs. Under its own terms, it may supply them without a prescription naming each person.

The 503A raw ingredient rules checked September 2026 set tests for what can be used. A substance must meet an official monograph if one applies. If no monograph applies, the ingredient can qualify through its use in a drug that FDA has approved. When neither test is met, the law requires a place on its 503A bulks list, which names additional raw ingredients permitted for this kind of compounding. The ingredient also needs a valid certificate showing its test results and must come from a manufacturer registered with FDA.

BPC-157 names a particular peptide ingredient, rather than a type of care. If it appears in an offer, ask which benefit is being promised and which evidence backs that claim. The FDA bulk-substance page lists BPC-157 in its table of withdrawn nominations; that page was current as of April 22, 2026. That means the groups that asked for it to be listed took back their requests; FDA still prints its safety concerns there.

Taking back a nomination does not add BPC-157 to FDA’s 503A bulks list; that remains the position checked November 3, 2026. A separate draft from HHS, the Department of Health and Human Services, was published October 30, 2026. HHS describes a conditional plan to hold off on enforcement for a state-licensed pharmacy or physician compounding for an individual patient’s prescription. The ingredients covered are semax, KPV, BPC-157, epitalon, TB-500 and MOTS-c. Each preparation must contain just one active ingredient and meet every condition in the draft. Blends fall outside the policy, along with 503B outsourcing facilities. The draft is nonbinding; it gives no peptide FDA approval. FDA’s 503A bulks list still contains none of these six peptides as of November 3, 2026.

Enforcement discretion is a hands-off approach: FDA does not plan to act if set terms are met. It is not approval.